Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

Ingo K. Mellinghoff; Maria Y. Wang; Igor Vivanco; Daphne A. Haas‐Kogan; Shaojun Zhu; Ederlyn Q. Dia; Kan Lu; Koji Yoshimoto; Julie H. Huang; Dennis J. Chute; Bridget L. Riggs; Steve Horvath; Linda M. Liau; Webster K. Cavenee; P. Nagesh Rao; Rameen Beroukhim; Timothy C. Peck; Jeffrey C. Lee; William R. Sellers; David Stokoe; Michael D. Prados; Timothy F. Cloughesy; Charles L. Sawyers; Paul S. Mischel

doi:10.1056/nejmoa051918

Abstract

Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors.

Keywords

PTENEpidermal growth factor receptorMedicineCancer researchErlotinibGliomaEGFR inhibitorsKinaseCancerInternal medicineOncologyBiologySignal transductionPI3K/AKT/mTOR pathwayGenetics

MeSH Terms

AdultAgedAntineoplastic AgentsDNANeoplasmErbB ReceptorsErlotinib HydrochlorideFemaleGefitinibGene AmplificationGene DeletionGene ExpressionGeneserbB-1GeneserbB-2GlioblastomaHumansMaleMiddle AgedMutationOligodendrogliomaPTEN PhosphohydrolasePolymerase Chain ReactionProtein Kinase InhibitorsQuinazolinesSequence AnalysisDNASignal Transduction

Affiliated Institutions

Related Publications

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Jessie Villanueva , Adina Vultur , John Tayu Lee +18 more

BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF...

2010 Cancer Cell 1218 citations

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

Saskia M. Brachmann , Irmgard Hofmann , Christian Schnell +6 more

NVP-BEZ235 is a dual PI3K/mTOR inhibitor currently in phase I clinical trials. We profiled this compound against a panel of breast tumor cell lines to identify the patient popul...

2009 Proceedings of the National Academy o... 316 citations

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry , Sandra Pavey , Christine A. Pratilas +26 more

Abstract Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. Th...

2010 Cancer Research 259 citations

Molecular Target Class Is Predictive of <i>In vitro</i> Response Profile

Joel Greshock , Kurtis E. Bachman , Yan Degenhardt +9 more

Abstract Preclinical cellular response profiling of tumor models has become a cornerstone in the development of novel cancer therapeutics. As efforts to predict clinical efficac...

2010 Cancer Research 123 citations

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Mohammad Atefi , Earl Avramis , Amanda Lassen +9 more

Abstract Purpose: PD-L1 is the main ligand for the immune inhibitory receptor PD-1. This ligand is frequently expressed by melanoma cells. In this study, we investigated whether...

2014 Clinical Cancer Research 323 citations

Publication Info

Year: 2005
Type: article
Volume: 353
Issue: 19
Pages: 2012-2024
Citations: 1439
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1439

OpenAlex

Influential

1144

CrossRef

Cite This

APA Style

                            
                                
                                    Ingo K. Mellinghoff, 
                                
                                    Maria Y. Wang, 
                                
                                    Igor Vivanco
                                
                                et al.
                            
                            (2005). 
                            Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. 
                            New England Journal of Medicine
                            , 353
                            (19)
                            , 2012-2024.
                            https://doi.org/10.1056/nejmoa051918
                        

Identifiers

DOI: 10.1056/nejmoa051918
PMID: 16282176

Data Quality

Data completeness: 86%